The launch of a new product can be a daunting task. The main reason this happens is that no matter how many times your company has managed to enter new…
Posts published in “Insights”
This article was originally published by Garth Boehm, Lixin Yao, Liang Hana, and Qiang Zheng in Acta Pharmaceutica Sinica under a creative commons license. Abstract The key events in the…
DrugPatentWatch can help identify generic entrants at the earliest stages Many clients come to DrugPatentWatch seeking to identify generic entrants well before they launch. CDMOs, equipment manufacturers, regulatory consultants, and…
The latest Swiss Biotech annual report focuses on the theme of shaping change. Change is a theme DrugPatentWatch is very familiar with — whether it is a matter of tracking…
This article was originally published by Christopher M. Holman* in Intellectual Property Watch under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Despite the important role of intellectual property rights in…
This paper was originally published by Maya Tannoury and Zouhair Attieh in Current Therapeutic Research under a creative commons license. Abstract Emerging markets represent an exceptional opportunity for the pharmaceutical…
When drugs are taken off the market because of concerns about their safety, it makes headlines. To access DrugPatentWatch’s list of discontinued drugs try a free trial or contact us…
Here’s a copy of the recent talk on Finding and Evaluating Branded and Generic Market Entry Opportunities. It’s based on the book Make Better Decisions, which distills insights gained from…
You would be surprised to find out just how many questions are answered by the analysis of the relationship that emerges between generic competition and drug prices. For manufacturers and…
Valuing pharma companies isn’t the same as valuing non-pharma companies, for several reasons. Traditional business considerations are compounded by patent law and FDA approval processes when evaluating the investment potential of…